Last reviewed · How we verify
Bupivacain/levobupivacaine
Bupivacain/levobupivacaine is a Local anesthetic Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently FDA-approved for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.
Bupivacaine and levobupivacaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Bupivacaine and levobupivacaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.
At a glance
| Generic name | Bupivacain/levobupivacaine |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
These drugs work by reversibly binding to and blocking voltage-gated sodium channels on the inner surface of nerve cell membranes. By preventing sodium influx, they inhibit depolarization and action potential generation, thereby blocking sensory and motor nerve conduction in a dose-dependent manner. Levobupivacaine is the S-enantiomer of bupivacaine, offering potentially improved cardiac safety profile while maintaining local anesthetic efficacy.
Approved indications
- Local and regional anesthesia for surgical procedures
- Infiltration anesthesia
- Nerve blocks
- Epidural and spinal anesthesia
Common side effects
- Hypotension
- Bradycardia
- Dizziness
- Nausea
- Systemic toxicity (CNS and cardiac effects at high doses)
Key clinical trials
- Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Groin Surgery (PHASE4)
- Catheter Outcomes With Sternotomy Cardiac Operated (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacain/levobupivacaine CI brief — competitive landscape report
- Bupivacain/levobupivacaine updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI
Frequently asked questions about Bupivacain/levobupivacaine
What is Bupivacain/levobupivacaine?
How does Bupivacain/levobupivacaine work?
What is Bupivacain/levobupivacaine used for?
Who makes Bupivacain/levobupivacaine?
What drug class is Bupivacain/levobupivacaine in?
What development phase is Bupivacain/levobupivacaine in?
What are the side effects of Bupivacain/levobupivacaine?
What does Bupivacain/levobupivacaine target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: University Hospital, Basel, Switzerland — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Local and regional anesthesia for surgical procedures
- Indication: Drugs for Infiltration anesthesia
- Indication: Drugs for Nerve blocks
- Compare: Bupivacain/levobupivacaine vs similar drugs
- Pricing: Bupivacain/levobupivacaine cost, discount & access